SrasV1, Main, Exploration, bibRecord, 003712

Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.

Identifieur interne : 003712 ( Main/Exploration ); précédent : 003711; suivant : 003713

Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.

Auteurs : Yunsheng Xu [République populaire de Chine] ; Zhengcai Jia ; Liyun Zhou ; Li Wang ; Jintao Li ; Yunfei Liang ; Tingting Zhao ; Bing Ni ; Yuzhang Wu

Source :

International immunopharmacology [ 1567-5769 ] ; 2007.

RBID : pubmed:17996696

Descripteurs français

KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (métabolisme), Anticorps antiviraux (toxicité), Anticorps antiviraux (usage thérapeutique), Equus caballus, Fragments Fab d'immunoglobuline (immunologie), Fragments Fab d'immunoglobuline (métabolisme), Fragments Fab d'immunoglobuline (toxicité), Fragments Fab d'immunoglobuline (usage thérapeutique), Macaca, Rats, Syndrome respiratoire aigu sévère (), Virus du SRAS (immunologie).
MESH :
- immunologie : Anticorps antiviraux, Fragments Fab d'immunoglobuline, Virus du SRAS.
- métabolisme : Anticorps antiviraux, Fragments Fab d'immunoglobuline.
- toxicité : Anticorps antiviraux, Fragments Fab d'immunoglobuline.
- usage thérapeutique : Anticorps antiviraux, Fragments Fab d'immunoglobuline.
- Animaux, Equus caballus, Macaca, Rats, Syndrome respiratoire aigu sévère.

English descriptors

KwdEn :
- Animals, Antibodies, Viral (immunology), Antibodies, Viral (metabolism), Antibodies, Viral (therapeutic use), Antibodies, Viral (toxicity), Horses, Immunoglobulin Fab Fragments (immunology), Immunoglobulin Fab Fragments (metabolism), Immunoglobulin Fab Fragments (therapeutic use), Immunoglobulin Fab Fragments (toxicity), Macaca, Rats, SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (therapy).
MESH :
- chemical , immunology : Antibodies, Viral, Immunoglobulin Fab Fragments.
- chemical , metabolism : Antibodies, Viral, Immunoglobulin Fab Fragments.
- chemical , therapeutic use : Antibodies, Viral, Immunoglobulin Fab Fragments.
- chemical , toxicity : Antibodies, Viral, Immunoglobulin Fab Fragments.
- immunology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- therapy : Severe Acute Respiratory Syndrome.
- Animals, Horses, Macaca, Rats.

Abstract

To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')(2) requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')(2) fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')(2) or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS-CoV F(ab')(2) in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab')(2). The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab')(2) indicate that this type of anti-SARS-CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS-CoV agents such as antiviral drug and vaccine.

DOI: 10.1016/j.intimp.2007.09.011
PubMed: 17996696

Affiliations:

République populaire de Chine

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.</title>
<author><name sortKey="Xu, Yunsheng" sort="Xu, Yunsheng" uniqKey="Xu Y" first="Yunsheng" last="Xu">Yunsheng Xu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000</wicri:regionArea>
<wicri:noRegion>Wenzhou 325000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jia, Zhengcai" sort="Jia, Zhengcai" uniqKey="Jia Z" first="Zhengcai" last="Jia">Zhengcai Jia</name>
</author>
<author><name sortKey="Zhou, Liyun" sort="Zhou, Liyun" uniqKey="Zhou L" first="Liyun" last="Zhou">Liyun Zhou</name>
</author>
<author><name sortKey="Wang, Li" sort="Wang, Li" uniqKey="Wang L" first="Li" last="Wang">Li Wang</name>
</author>
<author><name sortKey="Li, Jintao" sort="Li, Jintao" uniqKey="Li J" first="Jintao" last="Li">Jintao Li</name>
</author>
<author><name sortKey="Liang, Yunfei" sort="Liang, Yunfei" uniqKey="Liang Y" first="Yunfei" last="Liang">Yunfei Liang</name>
</author>
<author><name sortKey="Zhao, Tingting" sort="Zhao, Tingting" uniqKey="Zhao T" first="Tingting" last="Zhao">Tingting Zhao</name>
</author>
<author><name sortKey="Ni, Bing" sort="Ni, Bing" uniqKey="Ni B" first="Bing" last="Ni">Bing Ni</name>
</author>
<author><name sortKey="Wu, Yuzhang" sort="Wu, Yuzhang" uniqKey="Wu Y" first="Yuzhang" last="Wu">Yuzhang Wu</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17996696</idno>
<idno type="pmid">17996696</idno>
<idno type="doi">10.1016/j.intimp.2007.09.011</idno>
<idno type="wicri:Area/PubMed/Corpus">001C84</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C84</idno>
<idno type="wicri:Area/PubMed/Curation">001C84</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C84</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001E17</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001E17</idno>
<idno type="wicri:Area/Ncbi/Merge">001B07</idno>
<idno type="wicri:Area/Ncbi/Curation">001B07</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001B07</idno>
<idno type="wicri:doubleKey">1567-5769:2007:Xu Y:evaluation:of:the</idno>
<idno type="wicri:Area/Main/Merge">003854</idno>
<idno type="wicri:Area/Main/Curation">003712</idno>
<idno type="wicri:Area/Main/Exploration">003712</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.</title>
<author><name sortKey="Xu, Yunsheng" sort="Xu, Yunsheng" uniqKey="Xu Y" first="Yunsheng" last="Xu">Yunsheng Xu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000</wicri:regionArea>
<wicri:noRegion>Wenzhou 325000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jia, Zhengcai" sort="Jia, Zhengcai" uniqKey="Jia Z" first="Zhengcai" last="Jia">Zhengcai Jia</name>
</author>
<author><name sortKey="Zhou, Liyun" sort="Zhou, Liyun" uniqKey="Zhou L" first="Liyun" last="Zhou">Liyun Zhou</name>
</author>
<author><name sortKey="Wang, Li" sort="Wang, Li" uniqKey="Wang L" first="Li" last="Wang">Li Wang</name>
</author>
<author><name sortKey="Li, Jintao" sort="Li, Jintao" uniqKey="Li J" first="Jintao" last="Li">Jintao Li</name>
</author>
<author><name sortKey="Liang, Yunfei" sort="Liang, Yunfei" uniqKey="Liang Y" first="Yunfei" last="Liang">Yunfei Liang</name>
</author>
<author><name sortKey="Zhao, Tingting" sort="Zhao, Tingting" uniqKey="Zhao T" first="Tingting" last="Zhao">Tingting Zhao</name>
</author>
<author><name sortKey="Ni, Bing" sort="Ni, Bing" uniqKey="Ni B" first="Bing" last="Ni">Bing Ni</name>
</author>
<author><name sortKey="Wu, Yuzhang" sort="Wu, Yuzhang" uniqKey="Wu Y" first="Yuzhang" last="Wu">Yuzhang Wu</name>
</author>
</analytic>
<series><title level="j">International immunopharmacology</title>
<idno type="ISSN">1567-5769</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibodies, Viral (metabolism)</term>
<term>Antibodies, Viral (therapeutic use)</term>
<term>Antibodies, Viral (toxicity)</term>
<term>Horses</term>
<term>Immunoglobulin Fab Fragments (immunology)</term>
<term>Immunoglobulin Fab Fragments (metabolism)</term>
<term>Immunoglobulin Fab Fragments (therapeutic use)</term>
<term>Immunoglobulin Fab Fragments (toxicity)</term>
<term>Macaca</term>
<term>Rats</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Severe Acute Respiratory Syndrome (therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (métabolisme)</term>
<term>Anticorps antiviraux (toxicité)</term>
<term>Anticorps antiviraux (usage thérapeutique)</term>
<term>Equus caballus</term>
<term>Fragments Fab d'immunoglobuline (immunologie)</term>
<term>Fragments Fab d'immunoglobuline (métabolisme)</term>
<term>Fragments Fab d'immunoglobuline (toxicité)</term>
<term>Fragments Fab d'immunoglobuline (usage thérapeutique)</term>
<term>Macaca</term>
<term>Rats</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin Fab Fragments</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin Fab Fragments</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin Fab Fragments</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin Fab Fragments</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Fragments Fab d'immunoglobuline</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Fragments Fab d'immunoglobuline</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="toxicité" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Fragments Fab d'immunoglobuline</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Fragments Fab d'immunoglobuline</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Horses</term>
<term>Macaca</term>
<term>Rats</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Equus caballus</term>
<term>Macaca</term>
<term>Rats</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')(2) requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')(2) fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')(2) or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS-CoV F(ab')(2) in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab')(2). The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab')(2) indicate that this type of anti-SARS-CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS-CoV agents such as antiviral drug and vaccine.</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><noCountry><name sortKey="Jia, Zhengcai" sort="Jia, Zhengcai" uniqKey="Jia Z" first="Zhengcai" last="Jia">Zhengcai Jia</name>
<name sortKey="Li, Jintao" sort="Li, Jintao" uniqKey="Li J" first="Jintao" last="Li">Jintao Li</name>
<name sortKey="Liang, Yunfei" sort="Liang, Yunfei" uniqKey="Liang Y" first="Yunfei" last="Liang">Yunfei Liang</name>
<name sortKey="Ni, Bing" sort="Ni, Bing" uniqKey="Ni B" first="Bing" last="Ni">Bing Ni</name>
<name sortKey="Wang, Li" sort="Wang, Li" uniqKey="Wang L" first="Li" last="Wang">Li Wang</name>
<name sortKey="Wu, Yuzhang" sort="Wu, Yuzhang" uniqKey="Wu Y" first="Yuzhang" last="Wu">Yuzhang Wu</name>
<name sortKey="Zhao, Tingting" sort="Zhao, Tingting" uniqKey="Zhao T" first="Tingting" last="Zhao">Tingting Zhao</name>
<name sortKey="Zhou, Liyun" sort="Zhou, Liyun" uniqKey="Zhou L" first="Liyun" last="Zhou">Liyun Zhou</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Xu, Yunsheng" sort="Xu, Yunsheng" uniqKey="Xu Y" first="Yunsheng" last="Xu">Yunsheng Xu</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003712 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003712 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:17996696
   |texte=   Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:17996696" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.

Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.